Details for New Drug Application (NDA): 202012
✉ Email this page to a colleague
NDA 202012 describes EPROSARTAN MESYLATE, which is a drug marketed by Pharmobedient and is included in one NDA. Additional details are available on the EPROSARTAN MESYLATE profile page.
The generic ingredient in EPROSARTAN MESYLATE is eprosartan mesylate. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate profile page.
The generic ingredient in EPROSARTAN MESYLATE is eprosartan mesylate. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate profile page.
Summary for 202012
| Tradename: | EPROSARTAN MESYLATE |
| Applicant: | Pharmobedient |
| Ingredient: | eprosartan mesylate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 400MG BASE | ||||
| Approval Date: | Nov 16, 2011 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 600MG BASE | ||||
| Approval Date: | Nov 16, 2011 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
